TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03068351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
Study: NCT04431674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity Suspension for Injection
Description: MRI-guided ultrasound-stimulated microbubble-treatment
Study: NCT01644747

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)
Description: After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)
Description: After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
Study: NCT02091505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study: NCT01336400

Intervention type: OTHER
Intervention: single cell haplotyping
Description: We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.

Intervention type: OTHER
Intervention: single cell haplotyping
Description: We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
Study: NCT03911102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection
Study: NCT04458324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone Hydrochloride
Description: Subjects take 30 mg buspirone HCl twice a day for 6 months.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Buspirone Hydrochloride
Description: Subjects take 30 mg buspirone HCl twice a day for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buspirone placebo
Description: Subjects take a placebo tablet twice a day for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone placebo
Description: Subjects take a placebo tablet twice a day for 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation (NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Noninvasive Ventilation (NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Non-invasive ventilation (NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Non-invasive ventilation (NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Study: NCT04526821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Bovine Lactoferrin 600mg daily for 12 weeks (3 chewable tablets of 100mg , twice a day), for 12 weeks plus personal portection provided from the hospital.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin 600mg daily for 12 weeks (3 chewable tablets of 100mg, twice a day), for 12 weeks plus personal portection provided from the hospital.
Study: NCT01686893

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen insufflation with a TNI 20 oxy device
Description: Nasal oxygen insufflation with a TNI 20 oxy device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nasal Insufflation of oxygen
Description: Standard Nasal Insufflation of oxygen
Study: NCT01965873

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Same as arm description
Study: NCT02131129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration
Study: NCT02359708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical hand disinfection.
Description: Bacterial recolonization
Study: NCT02131129

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration
Study: NCT01712516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
Study: NCT03031002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure treatment for spider fear
Description: Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
Study: NCT01646333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory and Problem-Solving Intervention
Description: 8 weekly 1 hour sessions of memory compensation and problem-solving strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: 8 weekly 1 hour sessions of non-directive supportive therapy.
Study: NCT01712516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAB149
Description: QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237
Description: NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study: NCT00912119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid
Description: Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
Study: NCT03386019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphatic massage
Description: One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
Study: NCT03754439

Intervention type: BEHAVIORAL
Intervention: Physiological changes to noise and vibration exposure
Description: Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)

Intervention type: BEHAVIORAL
Intervention: Physiological changes to noise and vibration exposure
Description: Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
Study: NCT03269929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Subjects listened to music for 30 minutes before undergoing brachytherapy with spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Subjects received intravenous midazolam 0,02 mg/kgBW injection before undergoing brachytherapy with spinal anesthesia
Study: NCT00308581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 400mg Certolizumab Pegol, Q4W, administered 4-weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 400mg Certolizumab Pegol, Q2W, administered 2-weekly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo administered 4-weekly in Active 1
Study: NCT02438475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mynx Vascular Closure System
Description: MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.

Intervention type: OTHER
Group type: OTHER
Intervention: Manual Compression
Description: manual pressure applied to your groin for approximately 5-10 minutes
Study: NCT00899353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Fatty Acid
Description: Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
Study: NCT00494767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW869682
Description: GW869682 tablet with a dose strength of 250 mg will be available for subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW869682
Description: GW869682 tablet with a dose strength of 250 mg will be available for subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW869682
Description: GW869682 tablet with a dose strength of 250 mg will be available for subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW869682
Description: GW869682 tablet with a dose strength of 250 mg will be available for subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 tablet with a dose strength of 250 mg will be available for subjects
Study: NCT03386019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Description: In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
Study: NCT02388620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg
Study: NCT00494767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK189075
Description: GSK189075 tablet with a dose strength of 250 mg will be available for subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 tablet with a dose strength of 250 mg will be available for subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK189075
Description: GSK189075 tablet with a dose strength of 250 mg will be available for subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075-Placebo
Description: Placebo tablets to match GSK189075 250 mg will be available for subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK189075-Placebo
Description: Placebo tablets to match GSK189075 250 mg will be available for subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075-Placebo
Description: Placebo tablets to match GSK189075 250 mg will be available for subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK189075-Placebo
Description: Placebo tablets to match GSK189075 250 mg will be available for subjects
Study: NCT01501591

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxizine
Description: 25 mg orally, one time on two different days, 72 hours apart

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching placebo once on two different days, 72 hours apart.

Intervention type: DRUG
Group type: OTHER
Intervention: hydroxyzine/placebo
Description: 25 mg hydroxyzine or placebo once on two different days, 72 hours apart
Study: NCT00494767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW869682-Placebo
Description: Placebo tablets to match GW869682 250 mg will be available for subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW869682-Placebo
Description: Placebo tablets to match GW869682 250 mg will be available for subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW869682-Placebo
Description: Placebo tablets to match GW869682 250 mg will be available for subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW869682-Placebo
Description: Placebo tablets to match GW869682 250 mg will be available for subjects
Study: NCT01033149

Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine
Description: N-acetylcysteine, flexible dose 1200-2400mg/day
Study: NCT03005184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg bid
Description: oral medication during run-in and washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Description: oral medication
Study: NCT04172883

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment arm
Description: All pts are implanted with rATP enabled devices prior to the study start , the only intervention in both arms is switching on rATP and in the treatment arm programming changes done to optimize the rATP sequence delivery of therapy and prevent the patient from going into permanent or persistent AF
Study: NCT01579695

Intervention type: DRUG
Intervention: Tesamorelin for injection
Description: Daily 2 mg subcutaneous injections of Tesamorelin